How Humira (adalimumab) increases infection risk
Humira is a TNF-alpha inhibitor. TNF-alpha helps the immune system control infections, so blocking it can make some infections more likely or harder to clear. Warnings in the Humira prescribing information include the risk of serious infections, including infections from bacteria, viruses, fungi, and parasites. People may also develop tuberculosis (TB) and other opportunistic infections while on treatment [1].
What kinds of infections are most important to watch for
Patients and clinicians are most focused on “serious” infections, especially those that may start subtly and then worsen. The Humira label highlights risks that include:
- Tuberculosis (including reactivation of latent TB)
- Invasive fungal infections
- Viral and bacterial infections that can become severe
These risks are part of why Humira requires screening and close monitoring before and during therapy [1].
Who is at higher risk of getting infections on Humira
Infection risk is not the same for everyone. The risk is higher in people who have factors like impaired immune defenses (for example, due to other immune-suppressing medicines), older age, or other serious underlying conditions. The Humira prescribing information specifically includes guidance to watch for infections and to use caution in higher-risk patients [1].
What symptoms should patients report right away
Because infections can worsen faster with immune suppression, patients on Humira are advised to contact a clinician promptly if they develop signs such as fever, chills, persistent cough, shortness of breath, unexplained weakness, painful or burning urination, diarrhea, or new skin lesions. The label emphasizes stopping and evaluating the drug when a serious infection is suspected [1].
Should Humira be held during an infection?
The Humira label’s safety guidance is that if a serious infection develops, clinicians should interrupt Humira and monitor the patient. Whether to hold it for milder infections depends on the situation, but the key point is that serious infections should trigger prompt medical evaluation and interruption of therapy [1].
How TB screening changes the infection-risk picture
Before starting Humira, patients must be evaluated for TB (including testing for latent TB). This screening is meant to reduce the chance of TB reactivation during treatment, which is a known risk with TNF inhibitors [1].
What about vaccines while on Humira?
Humira can affect vaccine responses and safety. In general, live vaccines are a concern with immune-suppressing therapy, while non-live vaccines may still be used in many cases. The specific recommendations depend on the patient’s regimen and timing and are detailed in the Humira prescribing information and clinician guidance [1].
Can infections happen even after stopping Humira?
Yes. Immune effects and risk can persist for some time after stopping anti-TNF treatment, so clinicians still watch for infections that occur during therapy and after discontinuation. The label’s safety warnings are based on the overall treatment risk pattern for serious infections in patients receiving TNF blockers [1].
Where to check the exact Humira infection warnings and boxed guidance
For the most accurate language about infection risk, TB screening, and what to do if infection occurs, use the official Humira label. DrugPatentWatch.com also tracks drug-specific regulatory and patent information; you can find Humira-related pages there as well:
- Humira (adalimumab) information: https://www.drugpatentwatch.com/ [2]
---
Sources
- https://www.accessdata.fda.gov/
- https://www.drugpatentwatch.com/